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92 Session: Disease & Treatmentandmineralized nodules, and the highest levels ofmRNA expression of osteogenesis-
related genes collagen-1, ALPand BMP-2 in the osteoblasts. The in vivo studies found
that the rats in the 1 h group, 1.5 h group and 2 h group had significantly higher bone
mineral densities (BMD) than those of the control group, and the highest BMD was
obtained in the 1.5h group. The rats in the 0.5 h group and 3h group were not statis-
tically different in the BMD values with the control. The mechanical tests and bone
morphometrical analysis results revealed a similar tendency. The serum osteocalcin
level was the highest while the TRAP5b level was the lowest in the 1.5 h group.
Discussion and Conclusion: Our data has demonstrated that SEMF treatment at
1.5 h per day has the strongest osteogenic activity than other duration times in
the rat primary osteoblasts. The in vivo studies provided further supports that
SEMF treatment at 1.5 h per day increased the BMD of growing rats to the greatest
extent compared to other durations within 3 h. Our study suggests that the oste-
ogenic effects of SEMFs are duration-dependent and 1.5h per day is the optimal
duration for improving peak bone mass and may be used for the prevention and
treatment of osteoporosis.
http://dx.doi.org/10.1016/j.jot.2016.06.073147
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Objective: Long non-coding RNAs (lncRNAs), extensively transcribed from the
mammalian genome, have gained widespread attention in recent years. They serve
as important and powerful regulators of various biological activities and play crit-
ical roles in a variety of disease progression including differentiation. More and
more emerging evidence has demonstrated that some lncRNAs play important reg-
ulatory roles in osteoblast differentiation of MSCs, suggesting a potential therapeu-
tic strategy for bone formation. The lncRNA H19, one of the most well-known
imprinted genes, is located on human chromosome 11 and it is transcribed only
from the maternally inherited allele. Recent researches have highlighted H19 as
an active modulator in embryonic placental growth and skeletal muscle differen-
tiation. However, unfortunately, the role of H19 in osteoblast differentiation is
largely unknown and its function remains to be characterised.
Methods: Cultures of bone marrow-derived MSCs were established from a healthy
donor. The gene encoding human H19 was amplified and cloned into a pBABE retro-
virus vector. The H19 overexpression stable hMSCs were generated using retro-
virus-mediated gene delivery method as previously described. Osteogenic
differentiation was induced according to the published protocols and examined
by using ALP activity assay, Alizarin Red Staining, and marker genes expression.
Furthermore, the in vivo effect of H19 on osteogenesis was evaluated by ectopic
bone formation carried out in nude mice. Using bioinformatics tool, the candidate
miRNAs targeting were screened out and the direct interaction between H19 and
miRNA was identified by using a luciferase activity assay.
Results: In the present study, lncRNA H19 was found to be upregulated during
osteogenesis in human mesenchymal stem cells. Stable expression of H19 signifi-
cantly accelerated in vivo and in vitro osteoblast differentiation. Meanwhile, by
using bioinformatic investigations and RNA immunoprecipitation assays combined
with luciferase reporter assays, we successfully demonstrated that H19 functioned
as a miRNA sponge for miR-141 and miR-22, both of which were negative regulators
of osteogenesis. Further investigations revealed that H19 antagonized the endog-
enous functions of these two miRNAs and led to the de-repression of their shared
target gene b-catenin, which eventually activated the Wnt/b-catenin pathway and
hence potentiated osteogenesis. In addition, we also identified a novel regulatory
feedback loop between H19 and its encoded miR-675-5p. miR-675-5p was found to
directly target H19 and counteracted osteoblast differentiation.
Conclusion: Taken together, these findings indicate that the lncRNA H19 modu-
lates the Wnt/b-catenin pathway by acting as a competing endogenous RNA, which
may help to develop a novel therapeutic strategy for promoting fracture healing
and bone regeneration.
http://dx.doi.org/10.1016/j.jot.2016.06.074148
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Objective: Animal models of osteoarthritis (OA) are of considerable importance in
elucidating the underlying mechanisms of joint damage and providing proof of
concept in the development of pharmacological and biological agents that may
modify structural damage in the OA joint. Currently, there is still a lack of an
appropriate small animal model of OA which represents the underlying mecha-
nisms. Since transforming growth factor-beta/Smad (TGF-b/Smad) signalling
pathway has been identified as a key pathway in osteoarthritis (OA) initiation
and progression, we then hypothesise that animal models of OA could be estab-
lished by the interruption of TGF-b/Smad signalling. This study aims to investigate
the role of Smad7, one of the TGF-b/Smad signalling pathway inhibitors, in the
initiation and progression of OA, then further to evaluate whether Smad7 partial
knockout mouse is a good animal model of OA.
Methods: The genetically engineered Smad7DE1 (KO) and wild type (WT) mice (nZ
15) at the age of 6, 12, or 24 months were terminated for histological analysis. The
anterior cruciate ligament transection (ACLT) or sham operation were performed
in both the 6-month old Smad7 KO (nZ16) and WT (nZ16) mice. Histology, immu-
nohistochemistry (IHC), and micro-computed tomography (CT) analysis were per-
formed to determine the pathological changes in the articular cartilage and
subchondral bone after 6 weeks. The knee joints were harvested and subject to
histology and IHC examinations.
Results: Histological staining showed that there was no significant difference in
the articular cartilage between Smad7 KO and WT mice at 6, 12 or 24 months
old. However, cartilage hypertrophic markers (MMP13 and Col X) were significantly
upregulated in the intact Smad7 KO mice at 6-months, indicating Smad7 is essen-
tial for cartilage homeostasis. In the ACLT surgery model, six weeks after surgery,
typical OA phenotype characterised by cartilage destruction, osteophyte forma-
tion, and synovium inflammation were all found in the Smad7 KO mice, where
only mild degenerative changes were seen in the wild type control mice. Results
of Micro-CT showed total bone volume and bone mineral density of subchondral
bone were significantly increased in the Smad7 KO mice comparing to the wild
type mice after ACLT, indicating a bone hardening in the subchondral bone area.
Results of IHC also showed osteogenic marker Osterix was significantly upregulated
in the Smad7 KO mice after ACLT, suggesting enhanced bone formation.
Conclusion: Smad7 plays an important role in cartilage homeostasis. Lack of
Smad7 may contribute to OA intiation. Smad7 KO mice are susceptible to OA pro-
gression under mechanical instability conditions. Smad7 KO mice may be used as
an animal model of osteoarthritis to further study the underlying mechanisms.
http://dx.doi.org/10.1016/j.jot.2016.06.075152
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Background: Osteoarthritis (OA) is the most common degenerative joint disorder.
Inflammatory cytokines play an important role in OA progression. Previous studies
have demonstrated that ginsenoside Rb1 would prevent inflammation and
apoptosis in chondrocytes. However, we did not find any animal study that re-
ported the effect of Rb1 on attenuation of the severity of osteoarthritis.
Objective: In this study, we used a rat anterior cruciate ligament transection plus
medial meniscus resection (ACLT+MMx) model of OA and cell model to investigate
whether administration of ginsenoside Rb1 may attenuate the progression of
arthritis.
Methods: In the in vivo study, the 16-week-old male Sprague-Dawley rats were
divided into three groups: Group 1: sham control group; Group 2: Rb1-treated
